At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,172 enrolled
Drug / intervention
Letrozole +1 moredrug
Likely dose
Letrozole 2.5 mg orally once daily or Anastrozole 1 mg orally once dailyAI-extracted
Key inclusion· 5
- ✓Recent primary surgery for breast cancer
- ✓Early stage breast cancer
- ✓Postmenopausal status
- ✓Hormone receptor positive disease
Key exclusion· 3
- ✕Metastatic disease
- ✕Contralateral breast cancer including DCIS
- ✕Disease progression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
In Brief
A Phase 3 clinical trial evaluating Letrozole and Anastrozole for Breast Cancer. Completed, enrolled 4,172 participants across 259 sites in 20 countries.
Detailed Summary
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesAustralia, Austria, Belgium, Canada, China, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartDec 2005
Primary CompletionSep 2014
TodayJul 2026
First PostedNov 3, 2005
Enrollment StartDec 1, 2005
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 20.7 years ago
Interventions
Letrozoledrug
2.5 mg tablets
Anastrozoledrug
1 mg tablets